Elektrofi
Leo Takaoka has worked in various roles in the field of IP and patent counsel since 2007. Starting as a Senior Scientist at Schering-Plough Research Institute, they then moved to Scientist I, Department of Medicinal Chemistry at Millennium: The Takeda Oncology Company in 2009. In 2012, they were a Scientist, Department of Medicinal Chemistry at CoMentis, Inc., and also a Technology Specialist at WilmerHale LLP. In 2015, they were a Technology Specialist at Hamilton, Brook, Smith & Reynolds, P.C., and a Technical Advisor at Cooley LLP in 2016. From 2018 to 2019, they were a Technology Specialist at Foley Hoag LLP, and is currently a Director of IP and Patent Counsel at both Elektrofi and mytide Therapeutics.
Leo Takaoka attended UC Irvine from 1995-1998, where they earned a Bachelor of Arts (BA) in both Chemistry and Biology, General. Leo then continued their studies at UC Irvine, receiving a Ph.D. in Organic Chemistry in 2004. Following this, they worked as a Postdoctoral Fellow at Scripps Research from 2004-2007, specializing in Organic Synthesis. Finally, they attended Suffolk University Law School from 2013-2017, earning a Doctor of Law (J.D.).
This person is not in any teams
This person is not in any offices
Elektrofi
1 followers
Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions. Headquartered in Boston, the company’s founding team of MIT engineers and scientists are shaping the future of biologics delivery.